menu
    • menu
    [{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"VectorBuilder","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"UC101","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"Chengdu Yousino Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Yousino Biotechnology \/ VectorBuilder","highestDevelopmentStatusID":"5","companyTruncated":"Chengdu Yousino Biotechnology \/ VectorBuilder"},{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"Matrix Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Series A Financing","leadProduct":"AT19","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Chengdu Yousino Biotechnology","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Yousino Biotechnology \/ Matrix Partners","highestDevelopmentStatusID":"4","companyTruncated":"Chengdu Yousino Biotechnology \/ Matrix Partners"},{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"Chengdu Yousino Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"UCAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Chengdu Yousino Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chengdu Yousino Biotechnology \/ Ucello Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Yousino Biotechnology \/ Ucello Therapeutics"},{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"Chengdu Yousino Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Blood-Derived CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Chengdu Yousino Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chengdu Yousino Biotechnology \/ Chengdu Yousino Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Yousino Biotechnology \/ Chengdu Yousino Biotechnology"},{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"The General Hospital of Western Theater Command","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Claudin18.2 CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Chengdu Yousino Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chengdu Yousino Biotechnology \/ The General Hospital of Western Theater Command","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Yousino Biotechnology \/ The General Hospital of Western Theater Command"},{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"The General Hospital of Western Theater Command","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD19\/BCMA CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Chengdu Yousino Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chengdu Yousino Biotechnology \/ The General Hospital of Western Theater Command","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Yousino Biotechnology \/ The General Hospital of Western Theater Command"},{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"The General Hospital of Western Theater Command | Yancheng Third People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"UCAR-T Cell Therapy","moa":"CD19 | BCMA","graph1":"Immunology","graph2":"Phase I","graph3":"Chengdu Yousino Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chengdu Yousino Biotechnology \/ The General Hospital of Western Theater Command | Yancheng Third People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Yousino Biotechnology \/ The General Hospital of Western Theater Command | Yancheng Third People's Hospital"},{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"Chengdu Yousino Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD19 CAR T-Cell Therapy","moa":"CD-19","graph1":"Oncology","graph2":"Phase I","graph3":"Chengdu Yousino Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chengdu Yousino Biotechnology \/ Ucello Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Yousino Biotechnology \/ Ucello Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Chengdu Yousino Biotechnology

    Menu

    Chengdu Yousino Biotechnology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD19 CAR T-Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : The General Hospital of Western Theater Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous Bedside CD19 CAR T-cell Therapy for B-ALL

                            Details : CD19 CAR T-Cell Therapy is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 11, 2025

                            Lead Product(s) : CD19 CAR T-Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : The General Hospital of Western Theater Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UCAR-T Cell Therapy

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : The General Hospital of Western Theater Command | Yancheng Third People's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic UCB-derived CAR-T for SLE

                            Details : UCAR-T Cell Therapy is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 10, 2025

                            Lead Product(s) : UCAR-T Cell Therapy

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : The General Hospital of Western Theater Command | Yancheng Third People's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Claudin18.2 CAR-T

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The General Hospital of Western Theater Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CAR-T for Claudin18.2 Positive Solid Tumors

                            Details : Claudin18.2 CAR-T is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 05, 2025

                            Lead Product(s) : Claudin18.2 CAR-T

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The General Hospital of Western Theater Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD19/BCMA CAR-T Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The General Hospital of Western Theater Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CD19/BCMA CAR-T for SLE

                            Details : CD19/BCMA CAR-T Cell is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 05, 2025

                            Lead Product(s) : CD19/BCMA CAR-T Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The General Hospital of Western Theater Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Umbilical Cord Blood-Derived CAR-T

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : The General Hospital of Western Theater Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic UCB-derived CAR-T for B-ALL

                            Details : Allogeneic Umbilical Cord Blood-Derived CAR-T is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 01, 2025

                            Lead Product(s) : Allogeneic Umbilical Cord Blood-Derived CAR-T

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : The General Hospital of Western Theater Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UCAR-T Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Xi'an No.3 Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UCB-derived Dual-target BCMA/CD19 CAR-T in Relapsed/Refractory Multiple Myeloma

                            Details : UCAR-T Cell is a Cell and Gene therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 24, 2025

                            Lead Product(s) : UCAR-T Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Xi'an No.3 Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UC101

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : VectorBuilder

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VectorBuilder Enables FDA IND for Cord Blood CAR-T Therapy

                            Details : UC101 is the world’s first FDA IND-approved umbilical cord blood-derived allogeneic CAR-T therapy. It is being evaluated to alleviate the risk of host-versus-graft response.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 29, 2025

                            Lead Product(s) : UC101

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : VectorBuilder

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Chengdu Yousino Biotechnology

                            China arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT19

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Matrix Partners

                            Deal Size : $25.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Ucello Therapeutics Completes US$25 Million Series A Financing

                            Details : Proceeds from the financing will be used to advance the company's development of CAR-T technology platform CBT-X20, progress programs including lead asset AT19 through to US and China IND filings, and build a state of the art GMP-ready clinical manufactu...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            February 10, 2022

                            Lead Product(s) : AT19

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Matrix Partners

                            Deal Size : $25.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.